Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
Entrada Therapeutics announced positive topline data from Cohort 1 of its Phase 1/2 ELEVATE-44-201 study evaluating ENTR-601-44 for Duchenne muscular dystrophy (DMD) patients amenable to exon 44 skipping. The study demonstrated favorable safety and tolerability with no serious adverse events and showed statistically significant and clinically meani…